Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

10.1K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
10.1K
Folliculogenesis01:20

Folliculogenesis

1.3K
Folliculogenesis is the development of ovarian follicles, the specialized structures within the ovarian cortex where oogenesis, or egg development, occurs. This process is essential for female reproductive health and begins during fetal development when primordial follicles are formed. Each primordial follicle comprises a primary oocyte in the center, surrounded by a single layer of squamous pre-granulosa cells. These follicles remain dormant in late prophase I of meiosis until triggered by...
1.3K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

6.1K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
6.1K
Detailed Structure and Function of Lymph Nodes01:23

Detailed Structure and Function of Lymph Nodes

3.0K
Lymph nodes are bean-shaped structures that cluster along the lymphatic vessels in the inguinal, axillary, and cervical regions. Each node is divided into compartments by a capsule that extends trabeculae inward.
From a histological perspective, lymph nodes can be split into two main areas: the superficial cortex and the deep medulla. The outer cortex is populated by dendritic cells, macrophages, and B lymphocytes, which are densely packed into follicles. When these B-lymphocytes are presented...
3.0K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

5.6K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
5.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paraneoplastic Motor Neuropathy in Nodular Sclerosis Hodgkin's Lymphoma: Case Report.

Case reports in hematology·2026
Same author

Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Blood advances·2026
Same author

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Blood·2026
Same author

Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty.

Journal of geriatric oncology·2026
Same author

Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study.

Blood advances·2026

Related Experiment Video

Updated: Oct 12, 2025

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.4K

Early Progressing Follicular Lymphoma.

Danielle Wallace1, Carla Casulo2

  • 1James P. Wilmot Cancer Institute, University of Rochester Medical Center, 601 Elmwood Avenue Box 704, Rochester, NY, 14642, USA.

Current Oncology Reports
|November 19, 2021
PubMed
Summary

Predicting early progression in follicular lymphoma (POD24) remains challenging. Recent models and therapies offer hope for improved patient outcomes and personalized treatment strategies for high-risk individuals.

Keywords:
Early progressingFollicular lymphomaPOD24

More Related Videos

Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting
07:36

Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting

Published on: May 1, 2015

14.6K
Author Spotlight: Elucidating the Pathways of TFH Cell Differentiation in Acute LCMV Challenges
05:03

Author Spotlight: Elucidating the Pathways of TFH Cell Differentiation in Acute LCMV Challenges

Published on: April 26, 2024

841

Related Experiment Videos

Last Updated: Oct 12, 2025

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.4K
Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting
07:36

Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting

Published on: May 1, 2015

14.6K
Author Spotlight: Elucidating the Pathways of TFH Cell Differentiation in Acute LCMV Challenges
05:03

Author Spotlight: Elucidating the Pathways of TFH Cell Differentiation in Acute LCMV Challenges

Published on: April 26, 2024

841

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • Follicular lymphoma (FL) is an indolent non-Hodgkin lymphoma with generally good prognosis.
  • However, approximately 20% of FL patients experience progression of disease within 24 months (POD24), associated with poorer survival.
  • Current prediction models lack the definitive accuracy to identify patients at high risk for POD24.

Purpose of the Study:

  • To review recent literature on novel prediction models for POD24 in follicular lymphoma.
  • To discuss emerging management strategies and clinical trials for patients identified as high-risk for early progression.

Main Methods:

  • Review of recent scientific literature focusing on prediction models and treatment advancements for POD24 in FL.
  • Analysis of clinical trial data involving novel therapies and emerging treatment modalities.

Main Results:

  • Novel clinicopathologic prediction models are emerging, showing promise in identifying patients at risk of POD24.
  • Clinical trials have evaluated targeted therapies like tazemetostat, obinutuzumab, PI3K inhibitors, and lenalidomide for FL management.
  • Data on bispecific antibodies and CAR T-cell therapies for FL is anticipated.

Conclusions:

  • Accurate prediction of POD24 in follicular lymphoma is crucial for tailoring frontline management.
  • Ongoing research and novel therapeutic approaches are improving the outlook for patients at risk of early progression.
  • Future strategies aim to optimize treatment plans for POD24 patients to enhance survival outcomes.